Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Black Diamond Therapeutics (BDTX), a clinical-stage oncology company focused on developing MasterKey therapies for cancer patients, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Mark Velleca will engage in a fireside chat on June 4, 2025 from 4:20-4:50pm ET in New York. The company will also conduct one-on-one investor meetings during the event. A webcast of the presentation will be accessible through Black Diamond's website and remain archived for 90 days post-event.
Black Diamond Therapeutics (BDTX), un'azienda oncologica in fase clinica specializzata nello sviluppo di terapie MasterKey per pazienti affetti da cancro, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. L'amministratore delegato Mark Velleca parteciperà a una conversazione informale il 4 giugno 2025 dalle 16:20 alle 16:50 ET a New York. Durante l'evento, l'azienda terrà anche incontri individuali con gli investitori. La presentazione sarà trasmessa in webcast sul sito web di Black Diamond e resterà disponibile in archivio per 90 giorni dopo l'evento.
Black Diamond Therapeutics (BDTX), una empresa oncológica en etapa clínica enfocada en desarrollar terapias MasterKey para pacientes con cáncer, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. El CEO Mark Velleca participará en una charla informal el 4 de junio de 2025 de 4:20 a 4:50 pm ET en Nueva York. La empresa también realizará reuniones individuales con inversores durante el evento. La presentación estará disponible en webcast a través del sitio web de Black Diamond y permanecerá archivada por 90 días después del evento.
Black Diamond Therapeutics (BDTX)는 암 환자를 위한 MasterKey 치료법 개발에 주력하는 임상 단계의 종양학 회사로, 다가오는 Jefferies Global Healthcare Conference에 참여한다고 발표했습니다. CEO Mark Velleca는 2025년 6월 4일 뉴욕에서 동부 표준시 기준 오후 4시 20분부터 4시 50분까지 진행되는 화기애애한 대화에 참여할 예정입니다. 회사는 행사 기간 동안 일대일 투자자 미팅도 진행할 예정입니다. 발표 webcast는 Black Diamond 웹사이트를 통해 시청할 수 있으며, 행사 종료 후 90일간 아카이브로 제공됩니다.
Black Diamond Therapeutics (BDTX), une société oncologique en phase clinique spécialisée dans le développement de thérapies MasterKey pour les patients atteints de cancer, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. Le PDG Mark Velleca participera à une discussion informelle le 4 juin 2025 de 16h20 à 16h50 (heure de l'Est) à New York. La société tiendra également des réunions individuelles avec des investisseurs pendant l'événement. Une diffusion en webcast de la présentation sera accessible via le site web de Black Diamond et restera archivée pendant 90 jours après l'événement.
Black Diamond Therapeutics (BDTX), ein klinisch fortgeschrittenes Onkologieunternehmen, das sich auf die Entwicklung von MasterKey-Therapien für Krebspatienten spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference bekanntgegeben. CEO Mark Velleca wird am 4. Juni 2025 von 16:20 bis 16:50 Uhr ET in New York an einem informellen Gespräch teilnehmen. Das Unternehmen wird während der Veranstaltung auch Einzelgespräche mit Investoren führen. Ein Webcast der Präsentation wird über die Website von Black Diamond zugänglich sein und für 90 Tage nach der Veranstaltung archiviert bleiben.
- None.
- None.
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025 in New York, NY. In addition, the company will host one-on-one meetings with investors on the same day.
Presentation details are as follows:
- 4:20-4:50pm ET on Wednesday, June 4
The Webcast will be available at the start of the presentation on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. For more information, please visit www.blackdiamondtherapeutics.com.
Contacts
For Investors:
investors@bdtx.com
For Media:
media@bdtx.com
FAQ
When is Black Diamond Therapeutics (BDTX) presenting at the Jefferies Healthcare Conference 2025?
Who will represent BDTX at the Jefferies Global Healthcare Conference 2025?
How can investors access Black Diamond Therapeutics' Jefferies conference presentation?
What type of company is Black Diamond Therapeutics (BDTX)?
